BG96686A - Фармацевтичен състав,предназначен за въздействие върху ретикуло- ендотелната система,метод за получаване и приложението му - Google Patents

Фармацевтичен състав,предназначен за въздействие върху ретикуло- ендотелната система,метод за получаване и приложението му Download PDF

Info

Publication number
BG96686A
BG96686A BG096686A BG9668692A BG96686A BG 96686 A BG96686 A BG 96686A BG 096686 A BG096686 A BG 096686A BG 9668692 A BG9668692 A BG 9668692A BG 96686 A BG96686 A BG 96686A
Authority
BG
Bulgaria
Prior art keywords
acid
reticulo
pharmaceutical composition
composition intended
endothelial system
Prior art date
Application number
BG096686A
Other languages
English (en)
Other versions
BG61250B1 (bg
Inventor
Jozsef Beres
Jozsef Jun.
Original Assignee
Beres Export-Import Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beres Export-Import Rt. filed Critical Beres Export-Import Rt.
Publication of BG96686A publication Critical patent/BG96686A/bg
Publication of BG61250B1 publication Critical patent/BG61250B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Circuits Of Receivers In General (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

1. Фармацевтичен състав, предназначен за въздействие върху ретикуло-ендотелната система и за лечение на муковисцидоза и хронични болкови синдроми, произхождащи от дегенeративни лекомоторни заболявания или съпътстващи ги заболяванияс туморен произход, характеризиращ се с това, че съдържа следните компоненти: едно или повече фармацевтичноприемливи, водоразтворими съединения на бор, флуор, магнезий, ванадий, манган, желязо, кобалт, никел, мед, цинк и молибден, като тези съединения не могат да се утаяват съвместно или с други компоненти от състава и имат неутрална или кисела рН стойност във водна среда; аминооцетна киселина; глицерин; L-/+/-аскорбинова киселина; янтарна киселина; неутрална или кисела, водоразтворима, фармацевтично приемлива сол на етилендиаминтетраоцетната киселина; калиево-натриев тартарат и L-/+/-винена киселина.36 претенцииРН
BG96686A 1991-07-24 1992-07-24 Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му BG61250B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU912492A HU207799B (en) 1991-07-24 1991-07-24 Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (2)

Publication Number Publication Date
BG96686A true BG96686A (bg) 1993-12-24
BG61250B1 BG61250B1 (bg) 1997-04-30

Family

ID=10959658

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96686A BG61250B1 (bg) 1991-07-24 1992-07-24 Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му

Country Status (18)

Country Link
US (2) US5312629A (bg)
EP (1) EP0524633B1 (bg)
JP (1) JP2673852B2 (bg)
KR (1) KR100234855B1 (bg)
AT (1) ATE178213T1 (bg)
BG (1) BG61250B1 (bg)
CA (1) CA2074639C (bg)
CZ (1) CZ281672B6 (bg)
DE (1) DE69228777T2 (bg)
FI (1) FI923364A (bg)
HR (1) HRP920192B1 (bg)
HU (1) HU207799B (bg)
PL (1) PL169684B1 (bg)
RO (1) RO109505B1 (bg)
RU (1) RU2093160C1 (bg)
SI (1) SI9200155A (bg)
SK (1) SK278944B6 (bg)
YU (1) YU48243B (bg)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) * 1999-05-05 2000-03-10 Дубинина Лариса Васильевна Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) * 2000-09-29 2003-09-11 Steiner Gregory Gene Fluoride compositions and uses thereof
US6638431B2 (en) * 2001-05-03 2003-10-28 Mainstream Engineering Corporation Formulation and method for treating wetted surface elements in climate control systems
KR100889994B1 (ko) * 2003-08-14 2009-03-24 한영미 녹반을 함유하는 항암활성을 갖는 조성물
KR20050018250A (ko) * 2003-08-14 2005-02-23 한영주 복합생약 조성물을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
US20090214500A1 (en) * 2005-06-02 2009-08-27 U.S. Borax Inc. Prevention and treatment of osteochondrosis in animals and humans
MX2009005965A (es) * 2006-12-06 2009-06-17 United States Borax Inc Composiciones de alimento para animales.
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (en) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Enhancement of vanadium-containing phosphatase inhibitors by polyols
US10634385B2 (en) 2009-09-03 2020-04-28 Ademco Inc. Heat balancing system
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CA2912557A1 (en) 2013-06-07 2014-12-11 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
WO2015126265A1 (en) * 2014-02-18 2015-08-27 Santos Joyce Bedelia B Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
EP3138399B1 (en) 2014-04-30 2023-09-06 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) * 1978-06-26 1980-01-12 Peresu Yozefu Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

Also Published As

Publication number Publication date
JP2673852B2 (ja) 1997-11-05
YU81092A (sr) 1996-01-09
SK232692A3 (en) 1995-06-07
EP0524633A3 (en) 1993-07-28
HU207799B (en) 1993-06-28
PL169684B1 (pl) 1996-08-30
EP0524633A2 (en) 1993-01-27
CA2074639C (en) 1996-01-09
HUT61475A (en) 1993-01-28
HRP920192A2 (hr) 1994-04-30
PL295352A1 (en) 1993-02-22
US5312629A (en) 1994-05-17
SI9200155A (en) 1993-03-31
ATE178213T1 (de) 1999-04-15
CA2074639A1 (en) 1993-01-25
FI923364A0 (fi) 1992-07-24
RO109505B1 (ro) 1995-03-30
RU2093160C1 (ru) 1997-10-20
DE69228777T2 (de) 1999-10-21
HRP920192B1 (en) 2000-06-30
JPH06227992A (ja) 1994-08-16
CZ281672B6 (cs) 1996-12-11
US5405620A (en) 1995-04-11
KR930001915A (ko) 1993-02-22
EP0524633B1 (en) 1999-03-31
CZ232692A3 (en) 1993-02-17
SK278944B6 (sk) 1998-05-06
YU48243B (sh) 1997-08-22
KR100234855B1 (ko) 1999-12-15
FI923364A (fi) 1993-01-25
BG61250B1 (bg) 1997-04-30
HU912492D0 (en) 1991-12-30
DE69228777D1 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
BG96686A (bg) Фармацевтичен състав,предназначен за въздействие върху ретикуло- ендотелната система,метод за получаване и приложението му
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU1998583A (en) Pharmaceutical compositions of mopidamol
WO2002062356A3 (en) Monovalent-selective cation exchangers as oral sorbent therapy
CA2351620A1 (en) Nano-emulsion of 5-aminolevulinic acid
WO2005086960A3 (en) Narcotic-nsaid ion pairs
YU27499A (sh) Upotreba derivata 7-(2-oksa-5,8-diazabiciklo/4.3.0/non-8-il) -hinolin-karbonske kiseline za pripremanje farmaceutske kompozicije za tretiranje helikobakter-pilori infekcija i sa time povezanih gastroduodenskim oboljenjima
BR8905657A (pt) Processo para preparar um quelante bifuncional,processo para preparar um complexo de um composto,processo para preparar um conjugado e processo para preparar uma formulacao farmaceutica
CA2182987A1 (en) Novel phosphoric acid-amino acid complex salt and additive composition containing the salt and used in feed for ruminant mammals
CA2116192A1 (en) Highly concentrated tcf pharmaceutical preparations
ES8303440A1 (es) "procedimiento para la preparacion de acidos oxazafosforin-4-tio-alcansulfonicos".
ATE362756T1 (de) Schmerzfreie injektions-zubereitungen von 2- arylpropionsäuresalzen
Thompson et al. Separation of organophosphonates by ion chromatography with indirect photometric detection
CA2016470A1 (en) Pharmaceutical preparation and method of treatment for liver dysfunction
Votavova et al. Specificity of action of 6-hydroxydopamine in peripheral cat tissues:: Epletion of noradrenaline without depletion of 5-hydroxytryptamine
US3014026A (en) Chelates of monosaccharide-amino acids and related compounds
Dolfini et al. Studies with amphetamine in hyper-and hypothyroid rats
JPS5347479A (en) Water-soluble, partially deacetylated chitin and its preparation
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
AU5214900A (en) Pressed products of non-caking salt
ES2094200T3 (es) Composiciones herbicidas.
IE782515L (en) Treating diarrhoea
Preuss et al. Renal ammonia production in the presence of citric acid cycle blockade
AR008764A1 (es) Sales hidratadas de n,n'-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.
JPS57118510A (en) Method of increasing absorption of membrane-absorptive preparation on administration